Optum Rx shifts to fee-based

Pharmacy benefit managers are the middlemen between drugmakers, insurers, employers, and pharmacies. They decide formularies, negotiate rebates, and process claims. That gives them huge influence over what medicines cost on paper and what patients actually pay. The problem is that the business model has long been hard to see through. Optum Rx is now trying to change that by moving to a flat-fee structure instead of one tied to drug prices and prescription volume. (Healthcare Dive; UnitedHealth Group press release) ### What did Optum Rx actually announce? On May 11, Optum Rx said every PBM customer will be offered a new pricing model built around a defined monthly fee per member. The company framed it as a full redesign of how pharmacy benefits are priced and delivered, not a small pilot. The transition is supposed to roll out over the next 18 months, with the full model in place by the end of 2027. (UnitedHealth Group press release; Managed Healthcare Executive) ### What’s changing in the money flow? The big change is incentive design. Under the new setup, Optum Rx says its fees will no longer rise with a drug’s list price or with prescription volume. It also says it will eliminate spread pricing and similar practices, while passing 100% of negotiated rebates to clients. Basically, Optum is saying: pay us for the service directly, not through opaque margins buried inside the drug transaction. (UnitedHealth Group press release; Healthcare Finance News) ### Why is spread pricing such a loaded phrase? Spread pricing is when a PBM charges a health plan one amount for a drug claim but reimburses the pharmacy a lower amount, keeping the difference. Critics see that spread as a hidden markup. PBMs argue they help lower overall drug spending through negotiation and scale, but spread pricing has become one of the clearest symbols of why employers and lawmakers think the system is too opaque. Optum’s decision to phase it out is meant to answer that criticism head-on. (Healthcare Dive; Becker’s Hospital Review) ### Why do rebates distort things? Rebates sound like discounts, but they usually arrive after the sale and are negotiated off a drug’s list price. That can create a weird incentive — higher list prices can support bigger rebates, even if the net price falls later. Employers and plan sponsors have grown more skeptical of that setup because it makes it harder to tell whether the benefit design is actually lowering costs for members at the pharmacy counter. A flat-fee model tries to break that link. (Healthcare Finance News; Fierce Healthcare) ### Are buyers actually asking for this? Turns out, yes. A new Penta Group survey done for Evernorth, another major PBM operator, found more than 90% of employer benefit decision-makers said a rebate-free approach would be easier to understand and would improve transparency. The survey covered 300 employers, and 92% said passing savings directly to members instead of using rebates would improve transparency. That does not prove everyone will switch tomorrow, but it shows the market is moving. (Healthcare Dive; Fierce Healthcare) ### Is Optum the first big PBM to head this way? Not exactly in spirit, but this is one of the clearest moves yet from a top-three PBM. Evernorth rolled out its own rebate-free push in late 2025, with upfront discounts and a new pharmacy reimbursement model. So Optum is stepping into a lane that is already forming — one shaped by employer frustration, political scrutiny, and a broader push to make drug-benefit economics less of a black box. (Evernorth; Healthcare Finance News) ### What does this mean for patients? The immediate effect may be more visible for plan sponsors than for patients, because the contract shift happens upstream. But over time, the logic is simple — if PBM compensation is detached from list prices, there should be less reason to prefer high-list-price drugs that generate bigger rebates. Optum is also pairing the model with digital tools that show patients real-time medication pricing and pharmacy options before a prescription is filled. (UnitedHealth Group press release) ### So what’s the bottom line? This is really a fight over incentives. Optum Rx is betting that employers now want predictability and transparency more than the old rebate choreography. If that bet is right, the PBM business starts looking less like a hidden tollbooth and more like an explicit service contract — and competitors will have a harder time defending the old model.